GeNeuro publishes its 2022 Universal Registration Document
02 Mai 2023 - 7:30AM
Business Wire
Regulatory News:
GeNeuro (Euronext Paris: CH0308403085 – GNRO), a
biopharmaceutical company developing novel treatments for
neurodegenerative and autoimmune diseases such as multiple
sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe
consequences of COVID-19, (PASC, post-COVID or Long-COVID),
publishes its 2022 Universal Registration Document, in English,
which has been filed on April 28, 2023 with the “Autorité des
Marchés Financiers (AMF)”.
This document is available to the public free of charge, as
provided for in applicable legislation, and may be viewed and
downloaded on the Company’s website www.geneuro.com.
The 2022 Universal Registration Document includes the annual
financial report in XBRL format, the auditors’ reports and
information about fees paid to statutory auditors.
About GeNeuro
GeNeuro‘s mission is to develop safe and effective treatments
against neurological disorders and autoimmune diseases, such as
multiple sclerosis, by neutralizing causal factors encoded by
HERVs, which represent 8% of human DNA.
GeNeuro is based in Geneva, Switzerland and has R&D
facilities in Lyon, France. It has rights to 17 patent families
protecting its technology.
For more information, visit: www.geneuro.com
Disclaimer
This press release contains certain forward - looking statements
and estimates concerning GeNeuro’s financial condition, operating
results, strategy, projects and future performance and the markets
in which it operates. Such forward-looking statements and estimates
may be identified by words, such as “anticipate,” “believe,” “can,”
“could,” “estimate,” “expect,” “intend,” “is designed to,” “may,”
“might,” “plan,” “potential,” “predict,” “objective,” “should,” or
the negative of these and similar expressions. They incorporate all
topics that are not historical facts. Forward looking statements,
forecasts and estimates are based on management’s current
assumptions and assessment of risks, uncertainties and other
factors, known and unknown, which were deemed to be reasonable at
the time they were made but which may turn out to be incorrect.
Events and outcomes are difficult to predict and depend on factors
beyond the company’s control. Consequently, the actual results,
financial condition, performances and/or achievements of GeNeuro or
of the industry may turn out to differ materially from the future
results, performances or achievements expressed or implied by these
statements, forecasts and estimates. Owing to these uncertainties,
no representation is made as to the correctness or fairness of
these forward-looking statements, forecasts and estimates.
Furthermore, forward-looking statements, forecasts and estimates
speak only as of the date on which they are made, and GeNeuro
undertakes no obligation to update or revise any of them, whether
as a result of new information, future events or otherwise, except
as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230501005694/en/
GeNeuro Jesús Martin-Garcia Chairman and CEO +41 22 552
4800 investors@geneuro.com
NewCap (France) Mathilde Bohin / Louis-Victor Delouvrier
(investors) +33 1 44 71 98 52 Arthur Rouillé (media) +33 1 44 71 94
98 geneuro@newcap.eu
GeNeuro (EU:GNRO)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
GeNeuro (EU:GNRO)
Historical Stock Chart
Von Mai 2023 bis Mai 2024